Journal of Clinical Epidemiology
Volume 50, Issue 5 , Pages 557-569 , May 1997

Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis

  • Barbara G. Vickrey

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Barbara G. Vickrey, MD, MPH, UCLA Department of Neurology, C-128 RNRC; Box 951769, Los Angeles, CA 90095-1769.
    • From the Department of Neurology, University of California, Los Angeles, California 90095-1769 USA
    • Health Sciences Program, RAND, Santa Monica, California 90407-2138 USA
    • ,
  • Ron D. Hays

      Affiliations

    • From the Department of Medicine, University of California, Los Angeles, California 90095-1769 USA
    • Health Sciences Program, RAND, Santa Monica, California 90407-2138 USA
    • ,
  • Barbara J. Genovese

      Affiliations

    • Health Sciences Program, RAND, Santa Monica, California 90407-2138 USA
    • ,
  • Lawrence W. Myers

      Affiliations

    • From the Department of Neurology, University of California, Los Angeles, California 90095-1769 USA
    • ,
  • George W. Ellison

      Affiliations

    • From the Department of Neurology, University of California, Los Angeles, California 90095-1769 USA

,Accepted 22 January 1997.

References 

  1. Patrick D, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217–S232
  2. Bombardier C, Melfi CA, Paul J, Green R, Hawker G, Wright J, et al. Comparison of a generic and a disease-specific measure of pain and physical function after knee replacement surgery. Med Care. 1995;33:AS131–AS144 (suppl)
  3. Litwin M, Hays RD, Fink A, Ganz PA, Leake B, Leech GE, et al. Quality of life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129–135
  4. Parkerson GR, Connis RT, Broadhead WE, Patrick DL, Taylor TR, Tse CJ. Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients. Med Care. 1993;31:629–639
  5. Brownscombe IA, Laupacis A, Rice GPA, Ebers GC, Noseworthy JH. Development of a disease-specific quality of life measure for multiple sclerosis. Neurology. 1990;40(Suppl. 1):142
  6. Brownscombe IA. An evaluative health-related quality of life measure for multiple sclerosis. London, Ontario: Department of Epidemiology and Biostatistics, The University of Western Ontario; July 1990; Unpublished master's thesis
  7. Gulick EE. The self-administered ADL scale for persons with multiple sclerosis. In: 2nd edition.  Waltz CF,  Strickland OL editor. Measurement of Nursing Outcomes, Volume I; Measuring Client Outcomes. New York: Springer; 1988;p. 128–159
  8. Gulick EE. Self-assessed health and use of health services. West J Nurs Research. 1991;13:195–219
  9. Gulick EE. Concurrent validity for the ADL Self-Care Scale. In: Proceedings of the National Symposium of Nursing Research: Promoting Quality of Patient Care Through Research. San Francisco, CA. 1988;
  10. Gulick EE. Parsimony and model confirmation of the ADL self-care scale for multiple sclerosis persons. Nursing Res. 1987;36:278–283
  11. Gulick EE, Cook SD, Troiano R. Comparison of patient and staff assessment of MS patients' health status. Acta Neurol Scand. 1993;88:87–93
  12. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983;13:227–231
  13. Ware JE, Sherbourne CD. A 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  14. Hays RD, Sherbourne C, Mazel RM. The RAND 36-item health survey 1.0. Health Economics. 1993;2:217–227
  15. Likosky WH, Starr-Scheidkraut NJ, Wilson SR. Impact of the ‘Coping with MS effectively’ program on adaptive coping of MS patients. Neurology. 1995;45(Suppl. 4):334
  16. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: Reliability and validity in a patient population. Med Care. 1988;26:724–735
  17. Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M. The Medical Outcomes Study: An application of methods for monitoring the results of medical care. JAMA. 1989;262:925–930
  18. McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JFR. The validity and relative precision of the MOS short- and longform health status scales and Dartmouth COOP charts. Med Care. 1992;30:MS253–MS265
  19. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research. 1995;4:187–206
  20. Stewart AL, Hays RD, Ware JE. Health perceptions, energy fatigue, and health distress measures. In:  Stewart AL,  Ware JE editor. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992;p. 143–172
  21. Stewart AL, Ware JE, Sherbourne C, Wells KB. Psychological distress/well-being and cognitive functioning measures. In:  Stewart AL,  Ware JE editor. Measuring Functioning and Well- Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992;p. 102–142
  22. Sherbourne C. Social functioning: Sexual problems measures. In:  Stewart AL,  Ware JE editor. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992;p. 194–204
  23. Kurtzke JF. A proposal for a uniform minimal record of disability in multiple sclerosis. Acta Neurologica Scandinavica. 1981;64(Suppl. 87):110–129
  24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  25. Hadorn D, Hays RD. Multitrait-multimethod analysis of health-related quality of life preferences. Med Care. 1991;29:829–840
  26. Andrews FM, Withey SB. In: 2nd edition. Social Indicators of Well-Being: Americans' Perception of Life Quality. New York: Plenum Press; 1976;
  27. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619–626
  28. Jette AM, Cleary PD. Functional disability assessment. Phys Ther. 1987;67:1854–1859
  29. Jette AM, Davies AR, Cleary PD, et al.  The Functional Status Questionnaire: Reliability and validity when used in primary care. J Gen Intern Med. 1986;1:143–149
  30. Hays RD, Hayashi T. Beyond internal consistency reliability: Rationale and user's guide for the Multitrait Analysis Program on the microcomputer. Behav Res Methods Instruments Computers. 1990;22:167–175
  31. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334
  32. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: Statistics and strategies for evaluation. Controlled Clinical Trials. 1991;12:142S–158S
  33. Hays RD, Anderson R, Revicki DA. Psychometric evaluation and interpretation of health-related quality of life data. In:  Schumaker S,  Berzon R editor. The International Assessment of Health-Related Quality of Life: Theory, Translation, Measurement, and Analysis. Oxford, England: Rapid Communications; 1995;p. 103–114
  34. Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum. 1985;28:542–547
  35. SAS Institute . In: 2nd edition. SAS/ETS User's Guide. Cary, NC: SAS Institute; 1988; Version 6
  36. Hays RD, Brown JA, Spritzer KL, Dixon WJ, Brook RH. Consumer satisfaction with managed care: A study of 48 medical groups. In: 2nd edition. AHSR/FHSR Annual Meeting Abstract Book. 13:1996;p. 51–52
  37. Hays RD, Merz JF, Nicholas R. Response burden, reliability, and validity of the CAGE, Short-MAST, and AUDIT alcohol screening measures. Behavior Research Methods, Instruments, & Computers. 1995;27:277–280
  38. Vickrey BG, Hays RD, Myers L, Ellison G. Comparison of Three Health-Related Quality of Life Measures for Multiple Sclerosis. Executive Summary and Final Report to the National Multiple Sclerosis Society. 1994;
  39. Nunnally J. In: 2nd edition. Psychometric Theory. New York: McGraw-Hill; 1978;
  40. Vickrey BG, Hays RD, Rausch R, Engel J, Sutherling W, Brook RH. Quality of life of epilepsy surgery patients compared to outpatients with hypertension, diabetes, heart disease, and/or depressive symptoms. Epilepsia. 1994;35:597–607
  41. Huberty CJ. Problems with stepwise methods—better alternatives. Advances in Social Science Methodology. 1989;1:43–70
  42. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233
  43. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661
  44. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268–1276
  45. Goodkin DE, Rudick RA, VanderBrug Mendendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37:30–40
  46. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded placebo-controlled clinical trial. Ann Neurol. 1990;27:591–605
  47. van Diemen HAM, Polman CH, van Dongen TMMM, van Loenen AC, Nauta JJP, Taphoorn MJB, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992;32:123–130
  48. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain. 1989;112:133–146

☆ This research was supported by a grant from the Health Services Research Grant Program of the National Multiple Sclerosis Society. The National Institute of Neurological Disorders and Stroke provided support for Dr. Vickrey through a Clinical Investigator Development Award (K08 NS01669-02). Opinions are those of the authors and do not necessarily reflect the views of the sponsoring institutions, RAND, or the University of California, Los Angeles.

PII: S0895-4356(97)00001-2

Journal of Clinical Epidemiology
Volume 50, Issue 5 , Pages 557-569 , May 1997

Article Tools